Based on the key measurements obtained from Rapport Therapeutics,'s financial statements, Rapport Therapeutics, Common is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January. Key indicators impacting Rapport Therapeutics,'s financial strength include:
Comparative valuation techniques use various fundamental indicators to help in determining Rapport Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Rapport Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rapport Therapeutics, competition to find correlations between indicators driving Rapport Therapeutics,'s intrinsic value. More Info.
Rapport Therapeutics, Common is currently regarded number one company in current valuation category among its peers. It also is currently regarded as top stock in shares outstanding category among its peers creating about 0.09 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for Rapport Therapeutics, Common is roughly 11.70 . As of 12/02/2024, Common Stock Shares Outstanding is likely to drop to about 110.5 M. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rapport Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Rapport Therapeutics, Systematic Risk
Rapport Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rapport Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Rapport Therapeutics, correlated with the market. If Beta is less than 0 Rapport Therapeutics, generally moves in the opposite direction as compared to the market. If Rapport Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rapport Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rapport Therapeutics, is generally in the same direction as the market. If Beta > 1 Rapport Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Rapport Therapeutics, December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rapport Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rapport Therapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rapport Therapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Rapport Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rapport Therapeutics,'s daily price indicators and compare them against related drivers.
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.